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Abstract
Osteoarthritis (OA) is characterized by articular cartilage
degradation and hypertrophic bone changes with osteophyte
formation and abnormal bone remodeling. Two groups of OA
patients were identified via the production of variable and
opposite levels of prostaglandin E2 (PGE2) or leukotriene B4
(LTB4) by subchondral osteoblasts, PGE2 levels discriminating
between low and high subgroups. We studied whether the
expression of 5-lipoxygenase (5-LO) or 5-LO-activating protein
(FLAP) is responsible for the shunt from prostaglandins to
leukotrienes. FLAP mRNA levels varied in low and high OA
groups compared with normal, whereas mRNA levels of 5-LO
were similar in all osteoblasts. Selective inhibition of
cyclooxygenase-2 (COX-2) with NS-398-stimulated FLAP
expression in the high OA osteoblasts subgroup, whereas it was
without effect in the low OA osteoblasts subgroup. The addition
of PGE2 to the low OA osteoblasts subgroup decreased FLAP
expression but failed to affect it in the high OA osteoblasts
subgroup. LTB4 levels in OA osteoblasts were stimulated about
twofold by 1,25-dihydroxyvitamin D3  (1,25(OH)2D3) plus
transforming growth factor-β (TGF-β), a situation corresponding
to their effect on FLAP mRNA levels. Treatments with
1,25(OH)2D3  and TGF-β also modulated PGE2  production.
TGF-β stimulated PGE2  production in both OA osteoblast
groups, whereas 1,25(OH)2D3 alone had a limited effect but
decreased the effect of TGF-β in the low OA osteoblasts
subgroup. This modulation of PGE2 production was mirrored by
the synthesis of COX-2. IL-18 levels were only slightly increased
in a subgroup of OA osteoblasts compared with normal;
however, no relationship was observed overall between IL-18
and PGE2 levels in normal and OA osteoblasts. These results
suggest that the shunt from the production of PGE2 to LTB4 is
through regulation of the expression of FLAP, not 5-LO, in OA
osteoblasts. The expression of FLAP in OA osteoblasts is also
modulated differently by 1,25(OH)2D3 and TGF-β depending on
their endogenous low and high PGE2 levels.
Introduction
Osteoarthritis (OA) is the leading cause of disability among
the elderly population [1]. Despite its prevalence, we still do
not fully understand the etiology, pathogenesis and progres-
sion of this disease [2,3]. OA progresses slowly and has a
multifactorial origin. The disease is characterized by the deg-
radation and loss of articular cartilage, and hypertrophic bone
changes with osteophyte formation and subchondral plate
thickening [4,5]. It includes changes in articular cartilage and
surrounding bone, and an imbalance in loss of cartilage
through matrix degradation and an attempt to repair this matrix
[4,5]. Specific interactions between bone and cartilage have
not been clearly defined in OA; however, there is mounting evi-
dence to indicate a direct intervention of the bone
1,25(OH)2D3 = 1,25-dihydroxyvitamin D3; 5-LO = 5-lipoxygenase; BSA = bovine serum albumin; CICP = carboxy-terminal peptide fragment of col-
lagen type I; COX-2 = cyclooxygenase-2; ELISA = enzyme-linked immunosorbent assay; FLAP = 5-lipoxygenase-activating protein; GAPDH = glyc-
eraldehyde-3-phosphate dehydrogenase; IL = interleukin; LTB4 = leukotriene B4; LTs = leukotrienes; NSAIDs = non-steroidal anti-inflammatory drugs; 
OA = osteoarthritis; PGE2 = prostaglandin E2; RT-PCR = reverse transcriptase-mediated polymerase chain reaction; TGF-β = transforming growth 
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compartment in the initiation and progression of OA [6-8]. We
already identified that a growth factor, hepatocyte growth fac-
tor, is produced more abundantly by OA osteoblasts than by
normal osteoblasts, yet hepatocyte growth factor accumulates
in cartilage matrix and is more abundant in OA cartilage [9].
As the initiating events leading to OA are still poorly defined,
clinical intervention still targets the reduction of pain and dis-
comfort in afflicted patients. Conventional non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit cyclooxygenases (COX-1
and/or COX-2), the key enzymes that metabolize arachidonic
acid into prostaglandins and thromboxanes [10,11]. The
decrease in prostaglandin and thromboxane levels is probably
the basis for the anti-inflammatory and analgesic activity of the
NSAIDs that are widely used for the treatment of OA. Newer
drugs (coxibs) have in recent years targeted the selective
reduction of COX-2 activity because this inducible form is
expressed in response to inflammation, and coxibs are safer
for the gastrointestinal tract. However, long-term inhibition of
COX-2 could lead to a shunt to the 5-lipoxygenase (5-LO)
pathway, as we observed in vitro with OA osteoblasts [12],
leading to the formation of leukotrienes (LTs), which can
induce gastric lesions and ulceration [13,14]. The local pro-
duction of LTs in joint tissues is detrimental to tissues such as
the subchondral bone compartment. Indeed, the production of
LTs can promote bone resorption [15], and LTs are potent
chemoattractants and stimulators of inflammation [16-18].
Moreover, because the safety of coxibs is now in question, this
potential long-term effect on LT production could also be
detrimental.
Osteoblasts produce prostaglandins by both COX-1 and
COX-2 activities [19,20] and also produce LTs [12]. However,
the actual levels of prostaglandin E2 (PGE2) and LTs produced
in vivo in OA bone tissue are controversial [21,22]. We previ-
ously reported that the levels of LTs produced in vitro by OA
osteoblasts are either similar to or higher than normal as a
result of the endogenous production of PGE2 by these cells
[12], and indeed the endogenous production of PGE2 and of
IL-6 by OA osteoblasts separated OA patients into two sub-
groups: those producing normal PGE2 levels and those pro-
ducing high PGE2 levels [23]. Moreover, chronic inhibition of
COX-2 with a selective inhibitor such as NS-398 in OA oste-
oblasts enhanced the production of leukotriene B4 (LTB4)
[12], a situation also observed in other cell systems using
selective COX-2 inhibitors [24]. Hence, chronic inhibition of
COX-2 may promote abnormal 5-LO activity. The exact mech-
anism involved in this shunt toward the 5-LO pathway remains
obscure. The production of LTs requires active 5-LO in the
presence of calcium [25,26], yet arachidonic acid must be
presented by the 5-LO-activating protein [25,27]. In macro-
phages, the shunt from the COX to the 5-LO pathway is due
to an increase in 5-LO expression [28,29], whereas in alveolar
macrophages and in neutrophils it is due to altered 5-lipoxyge-
nase-activating protein (FLAP) expression [30,31]. Whether
PGE2 directly modulates the production of LTs in osteoblasts
remains unknown. However, the inhibition of the production of
LTs in macrophages is due to high PGE2 levels as a result of
an increase in IL-10 [24], whereas in neutrophils IL-18 stimu-
lates the production of LTs [32].
The aim of this study was to explore the mechanisms respon-
sible for the shunt from the COX to the 5-LO pathway in
human OA osteoblasts. We also examined the implication of
both 5-LO and FLAP in the production of LTB4 in these cells
and the factors that might modulate their expression. We also
sought to determine whether there was a relationship between
PGE2 levels and either IL-10 or IL-18 levels in OA osteoblasts.
Materials and methods
Patients and clinical parameters
Tibial plateaux were dissected away from the remaining carti-
lage and trabecular bone under sterile conditions from OA
patients who had undergone total knee replacement surgery
as described previously [23,33-35]. A total of 35 patients
(aged 68.8 ± 7.6 years (mean ± SD); 7 males, 28 females)
classified as having OA, as defined in the recognized clinical
criteria of the American College of Rheumatology, were
included in this study [36]. None of the patients had received
medication that would interfere with bone metabolism, includ-
ing corticosteroids, for six months before surgery. A total of 18
subchondral bone specimens of tibial plateaux from normal
individuals (aged 62.2 ± 14.3 years (mean ± SD); 11 males,
7 females) were collected at autopsy within 16 hours of death.
These were used after it had been established that they had
not been on any medication that could interfere with bone
metabolism and had not had any bone metabolic disease. Indi-
viduals showing abnormal cartilage macroscopic changes
and/or subchondral bone plate sclerosis were not included in
the normal group. All human materials were acquired after
obtaining signed agreement from patients undergoing knee
surgery, or from their relatives for the specimens collected at
autopsy in accordance with the guidelines of the Clinical
Research Ethics Committee of the Centre Hospitalier de l'Uni-
versité de Montréal.
Preparation of primary subchondral bone cell culture
Isolation of subchondral bone plate and the cell cultures from
the non-sclerotic and sclerotic areas were prepared as
described previously [33,34,37,38]. At confluence, cells were
passaged once at 25,000 cells/cm2 and grown for 5 days in
Ham's F12/DMEM medium (Sigma-Aldrich, Oakville, Ontario,
Canada) containing 10% fetal bovine serum before specific
assays. Conditioning was performed for a further 24 hours in
serum-free Ham's F12/DMEM medium. Confluent cells were
incubated in the presence or absence of 1,25-dihydroxyvita-
min D3 (1,25(OH)2D3; 50 nM) for 48 hours. Supernatants
were collected at the end of the incubation and kept at -80°C
before assays. Cells were prepared for either SDS-PAGE sep-
aration or RT-PCR experiments. Cells prepared for SDS-Available online http://arthritis-research.com/content/8/6/R181
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PAGE separation were lysed with RIPA buffer (50 mM Tris-
HCl pH 7.4, 1% Nonidet P40, 0.5% sodium deoxycholate,
0.1% SDS, 150 mM NaCl containing the following inhibitors:
10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml pepstatin,
10 μg/ml O-phenanthroline, 1 mM sodium orthovanadate and
1 mM dithiothreitol), and kept at -80°C before assays. Protein
determination was performed by the bicinchoninic acid
method [39].
Measurement of PGE2, IL-10 and IL-18 content in culture 
medium
The concentration of PGE2, IL-10 and IL-18 was determined
in culture medium of confluent cells incubated for their last 48
hours in Ham's F12/DMEM containing 1% ITS. Specific ELI-
SAs from Cayman Chemicals (Ann Arbor, MI, USA) for PGE2
(specificity 100%, sensitivity 7.8 pg/ml), from R&D Systems
(Minneapolis, MN, USA) for IL-10 and from Medical and Bio-
logical Laboratories Co (Nagoya, Japan) for IL-18 (specificity
100% for both, sensitivity 0.5 pg/ml for IL-10 and 12.5 pg/ml
for IL-18) were used as described in the manufacturer's man-
ual. All determinations were performed in triplicate for each
cell culture.
RNA extraction and RT-PCR assays
Total cellular RNA from normal and OA osteoblasts was
extracted with TRIzol™ reagent (Invitrogen, Burlington,
Ontario, Canada) in accordance with the manufacturer's spec-
ifications and than treated with the DNA-free™ DNase Treat-
ment and Removal kit (Ambion, Austin, TX, USA) to ensure the
complete removal of chromosomal DNA. The RNA was quan-
tified with the RiboGreen RNA quantification kit (Molecular
Probes, Eugene, OR, USA). The RT reactions were primed
with random hexamers with 2 μg of total RNA in a 100 μl final
reaction volume followed by PCR amplification as described
previously [35]. 5-LO and FLAP PCR products of 467 and
399 base pairs, respectively, were generated by PCR amplifi-
cation with the use of 20 pmol of each primer 5'-CTG TTC
CTG GGC ATG TAC CC-3' (sense) and 5'-GAC ATC TAT
CAG TGG TCG TG-3' (antisense), and 5'-AAT GGG AGG
AGC TTC CAG AG-3' (sense) and 5'-ACC AAC CCC ATA
TTC AGC AG-3' (antisense). To ensure equivalent loading,
glyceraldehyde-3-phosphate  dehydrogenase (GAPDH) was
amplified in the same solution, with the use of 20 pmol of each
primer 5'-CAG AAC ATC ATC CCT GCC TCT-3' (sense) and
5'-GCT TGA CAA AGT GGT CGT TGAG-3' (antisense) to
generate a predicted amplified sequence of 360 base pairs
[40]. However, the amplification of 5-LO and FLAP mRNA
species was performed separately from that of GAPDH mRNA
to avoid substrate depletion. Our preliminary results indicated
that we were still in the linear portion of the amplification of
GAPDH with 25 cycles and of 5-LO or FLAP with 35 cycles;
PCR amplifications were therefore performed with these
respective numbers of cycles. After amplification, DNA was
analyzed on an agarose gel and revealed by ultraviolet detec-
tion. Densitometric analysis was performed for each amplimer
against that for GAPDH with a ChemiImager 4000 (Alpha
Innotech Corporation, San Leandro, CA, USA). The results are
presented as the relative expression of Coll1A1 and Coll1A2
normalized to the housekeeping gene GAPDH.
Real-time PCR
Real-time quantification of 5-LO, FLAP and GAPDH mRNA
was performed in the GeneAmp 5700 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) with the
2X Quantitect SYBR Green PCR Master Mix (Qiagen) used in
accordance with the manufacturer's specifications. In brief,
100 ng of the cDNA obtained from the RT reactions were
amplified in a total volume of 50 μl consisting of 1 × Master
mix, 0.5 unit of uracil-N-glycosylase (UNG; Epicentre Technol-
ogies, Madison, WI, USA) and the gene-specific primers
described above, which were added at a final concentration of
200 nM. The tubes were first incubated for 2 minutes at 50°C
(UNG reaction), then at 95°C for 15 minutes (UNG inactiva-
tion and polymerase activation) followed by 40 cycles each
consisting of denaturation (94°C for 15 seconds), annealing
(60°C for 30 seconds), extension (72°C for 30 seconds) and
data acquisition (77°C for 15 seconds). The data were col-
lected and processed with the GeneAmp 5700 SDS software
and given as threshold cycle (Ct), corresponding to the PCR
cycle at which an increase in reporter fluorescence above
baseline signal could first be detected. When comparing nor-
mal and OA basal expression levels, the Ct values were con-
verted to numbers of molecules and the values for each
sample were calculated as the ratio of the number of mole-
cules of the target gene to the number of molecules of
GAPDH.
Western blot analysis of cyclooxygenase-2 (COX-2) 
levels in OA osteoblasts
Cell extracts were loaded on a 10% polyacrylamide gel and
separated by SDS-PAGE under reducing conditions [41]. The
proteins were then transferred electrophoretically to a
poly(vinylidene difluoride) membrane (Boehringer Mannheim,
Penzberg, Germany), and Western blotting was performed as
described in the Enhanced Chemiluminescence (ECL) Plus
detection system's manual (Pierce, Brockville, Ontario, Can-
ada). COX-2 levels were determined with a polyclonal rabbit
anti-human COX-2 antibody (Cayman Chemical-Cedarlane,
Hornby, Ontario, Canada) at a 1:400 dilution. The secondary
antibody used for the detection of the rabbit anti-human COX-
2 was a goat anti-rabbit IgG (1:20,000 dilution) from Upstate
Biotechnology (Lake Placid, NY, USA). Densitometric analysis
of Western blot films was performed with a Macintosh MacOS
9.1 computer using the public-domain NIH Image program
developed at the US National Institutes of Health with the
Scion Image 1.63 program [42].Arthritis Research & Therapy    Vol 8 No 6    Maxis et al.
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Phenotypic characterization of human subchondral 
osteoblast cell cultures
Phenotypic features of osteoblast cultures were determined
by evaluating 1,25(OH)2D3-dependent (50 nM) alkaline phos-
phatase activity and osteocalcin release. Alkaline phosphatase
activity was determined on cell aliquots by substrate hydrolysis
with p-nitrophenyl phosphate, and osteocalcin release was
determined in cell supernatants with an enzyme immunoassay
as described previously [23,34]. Collagen synthesis was
determined as the de novo release of the carboxy-terminal
peptide fragment of collagen type I (CICP), reflecting true col-
lagen synthesis. CICP was determined with a selective ELISA
(Quidel Corporation, Cedarlane, Hornby, Ontario, Canada) in
conditioned medium from confluent normal and OA osteob-
lasts incubated for 48 hours in Ham's F12/DMEM medium
containing 0.5% BSA. CICP release was then reported as ng
per mg of cellular protein.
Statistical analysis
All quantitative data are expressed as means ± SEM. The data
were analyzed with Student's t test; and p < 0.05 was consid-
ered statistically significant.
Results
Determination of two population of OA patients
As we observed previously [23,34], OA osteoblasts pre-
sented an altered phenotype from that of normal osteoblasts.
This was demonstrated by an elevated alkaline phosphatase
activity and osteocalcin release in response to stimulation with
1,25(OH)2D3, and an enhanced production of collagen type I
(Table 1). Under the present culture conditions, osteoblasts
expressed bone-specific type I collagen without any contami-
nation from cartilage-specific type II collagen [23]. Osteob-
lasts isolated from OA patients also presented variable
endogenous PGE2 production, as shown previously [12,23].
We therefore separated our OA patients into low and high cat-
egories on the basis of PGE2 production, with reciprocal levels
of LTB4 produced by these cells (Figure 1). However, regard-
less of their endogenous production of PGE2, phenotypic
characteristics were similar between cell cultures of OA oste-
oblasts as previously reported [23], and this variable PGE2
production was due to alterations in COX-2 production [43].
Regulation of expression of 5-LO and FLAP
On the basis of PGE2 production, we next questioned what
mechanism or mechanisms were responsible for the alteration
of LTB4 production. We measured the expression of the two
key enzymes involved in LT production, 5-LO and FLAP (Fig-
ure 2). The expression of 5-LO, although slightly lower in the
high OA group, was not significantly different between normal
and OA patients (Figure 2a), yet the expression of FLAP was
variable (Figure 2b). Indeed, FLAP expression was highest in
those patients with the lowest PGE2 levels, whereas FLAP
expression was similar to normal in OA osteoblasts with the
highest PGE2 levels. To determine the mechanism responsible
for this shunt between the production of PGE2 and that of
LTB4 in OA osteoblasts, we then determined the effect of the
addition of PGE2 to osteoblasts or of an inhibitor of PGE2 pro-
duction on the expression of FLAP by real-time PCR. As
shown in Figure 3, FLAP expression in normal cells did not
vary much with the applied treatments except for a small but
significant increase in response to NS-398, a selective COX-
2 inhibitor. In low OA osteoblasts, PGE2  treatments
decreased FLAP expression about 2.5-fold (p  < 0.025),
whereas inhibiting endogenous PGE2 production with NS-
398 did not inhibit FLAP expression. In high OA osteoblasts
Table 1
Evaluation of phenotypic markers of normal and osteoarthritis 
(OA) subchondral osteoblasts
Source Alkaline 
phosphatase 
(nmol/mg 
protein/30 min)
Osteocalcin (ng/
mg protein/48 
hours)
Collagen type I 
(ng/mg protein/
48 hours)
Normal (n = 11) 624.7 ± 88.8 176.6 ± 24.7 285.3 ± 17.1
OA (n = 26) 1333.1 ± 215.7 264.0 ± 20.7 370.4 ± 8.1
p < 0.005 p < 0.05 p < 0.015
Confluent osteoblasts were incubated for their last 2 days of culture 
in Ham's F12/DMEM medium containing 2% charcoal-treated fetal 
bovine serum and 50 nM 1,25-dihydroxyvitamin D3. Values are 
means ± SEM. The statistical analysis compared OA values with 
their respective normal values.
Figure 1
Relationship between PGE2 and LTB4 levels in normal and osteoarthri- tis osteoblasts Relationship between PGE2 and LTB4 levels in normal and osteoarthri-
tis osteoblasts. Cells were grown to confluence in Ham's F12/DMEM 
medium containing 10% fetal bovine serum. Confluent cells were incu-
bated for their last 48 hours in serum-free medium containing 1% insu-
lin-transferrin-selenium mix (ITS). Prostaglandin E2 (PGE2) and 
leukotriene B4 (LTB4) levels were measured with selective ELISA. Data 
points represent values for individual cell cultures. Low osteoarthritis 
(OA) and high OA were separated on the basis of their PGE2 levels: 
high OA had PGE2 levels at least 2 SD above the mean normal PGE2 
levels. Normal samples, n = 10; low OA, n = 14; high OA, n = 8.Available online http://arthritis-research.com/content/8/6/R181
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with already high PGE2 levels, the addition of PGE2 failed to
modify FLAP expression, whereas inhibiting PGE2 production
with NS-398 enhanced FLAP expression about 4-fold (p <
0.025). Such an increase in FLAP expression in response to
NS-398 could explain our previous observation of an increase
in LTB4 production by OA osteoblasts under similar conditions
[12]. In contrast, under similar experimental conditions with
PGE2 or NS-398, 5-LO expression did not vary significantly in
either normal or OA osteoblasts (not shown).
We then evaluated the modulation of LTB4 production in OA
osteoblasts by 1,25(OH)2D3, transforming growth factor-β
(TGF-β) or a combination of the two because both factors
have been shown to modulate the activity and/or expression of
FLAP in other cell systems [28,30,31,44-46]. As shown in Fig-
ure 4, OA osteoblasts responded to 1,25(OH)2D3, TGF-β or a
combination of the two with an increase in LTB4 production,
regardless of their endogenous PGE2 production; data were
therefore pooled for both groups of OA osteoblasts. The effect
of 1,25(OH)2D3 and TGF-β was additive in this particular set-
ting. This effect was not due to any significant modification of
5-LO expression in these cells (not shown). In contrast, when
we evaluated the expression of FLAP, this varied with the
applied treatment (Figure 5). In addition, the expression of
FLAP was variable in response to TGF-β treatment depending
on the subgroup (low or high) of OA patients.
Figure 2
Real-time RT-PCR analysis of 5-LO and FLAP mRNA isolated from nor- mal and osteoarthritis osteoblasts Real-time RT-PCR analysis of 5-LO and FLAP mRNA isolated from nor-
mal and osteoarthritis osteoblasts. Confluent cells were incubated for 
their last 48 hours in Ham's F12/DMEM medium containing 0.5% BSA. 
Cells were lyzed with TRIzol and RNA extracted according to the proto-
col described in the Materials and methods section. Plasmid DNAs 
containing the target gene sequences were used to generate standard 
curves. When comparing normal and osteoarthritis (OA) osteoblast 
expression levels, values were converted to numbers of molecules and 
the values for each sample were calculated as the ratio of the number 
of molecules of 5-lipoxygenase (5-LO) (a) or 5-LO-activating protein 
(FLAP) (b) to the number of molecules of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Values are means ± SEM for n = 4 samples 
for all conditions.
Figure 3
Regulation of FLAP mRNA expression by PGE2 and NS-398 in normal  and osteoarthritis osteoblasts Regulation of FLAP mRNA expression by PGE2 and NS-398 in normal 
and osteoarthritis osteoblasts. Confluent cells were incubated for their 
last 48 hours in Ham's F12/DMEM medium containing 0.5% BSA in 
the presence or absence of 500 nM prostaglandin E2 (PGE2) or 10 μM 
NS-398. 5-Lipoxygenase-activating protein (FLAP) expression was 
measured as described in the legend to Figure 2. Values are means ± 
SEM; p values compare data with basal values in each group. Normal 
samples, n = 3; low and high osteoarthritis (OA), n = 5 for each group. 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 4
Modulation of LTB4 production by 1,25(OH)2D3 and TGF-β in osteoar- thritis osteoblasts Modulation of LTB4 production by 1,25(OH)2D3 and TGF-β in osteoar-
thritis osteoblasts. Confluent cells were incubated for their last 48 
hours in Ham's F12/DMEM medium containing 2% fetal bovine serum 
in the presence or absence of 50 nM 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3), 10 ng/ml transforming growth factor-β (TGF-β), or 
both. Leukotriene B4 (LTB4) was measured in conditioned medium with 
the use of a very selective ELISA. Values are means ± SEM for n = 4 
samples for all groups.Arthritis Research & Therapy    Vol 8 No 6    Maxis et al.
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Because we observed variations in LTB4 production (Figure 4)
and FLAP expression (Figure 5) in response to 1,25(OH)2D3,
TGF-β or both, we next examined whether PGE2 production
varied with these treatments and whether this could be linked
with a modulation of COX-2 synthesis. PGE2 production by
isolated OA osteoblasts was enhanced by TGF-β in both the
low and high OA subgroups of patients (Figure 6), whereas
1,25(OH)2D3 was without significant effect in both groups.
However, whereas 1,25(OH)2D3  significantly inhibited the
stimulating effect of TGF-β in the low OA subgroup, it was
without significant effect in the high OA subgroup (Figure 6).
This effect of TGF-β and 1,25(OH)2D3 on PGE2 production
was reflected by a similar effect on COX-2 synthesis respon-
sible for PGE2 production (Figure 6, bottom panel). Indeed,
TGF-β significantly increased COX-2 synthesis by about 97 ±
37% (p  < 0.05 versus basal values), and the addition of
1,25(OH)2D3 with TGF-β caused a small decrease compared
with TGF-β alone (42 ± 17% decrease, p < 0.05).
Relationship between PGE2 levels and IL-10 and IL-18
In macrophages, the shunt from the COX to the 5-LO pathway
is linked with a variable production of IL-10; as PGE2 levels
rise, IL-10 levels increase and inhibit the synthesis of LTB4
[24]. Unfortunately, in our cell culture system IL-10 levels were
very low, close to the detection limit, and failed to vary with
PGE2 levels (not shown). A link between IL-18 and PGE2 lev-
els in the synovial fluid of patients with OA of the knee has also
been established [47], and IL-18 upregulates LTs production
in neutrophils [32]. In OA osteoblasts, the levels of IL-18 were
generally slightly higher than normal. However, no clear
relationship between IL-18 and PGE2  levels could be
observed in OA osteoblasts except in a limited subgroup of
patients (Figure 7).
Discussion
This study provides the first comprehensive explanation about
the regulation of the expression of the enzymatic system
responsible for LT synthesis in osteoblasts. It also revealed
new and unique mechanisms of regulation of FLAP expression
in OA osteoblasts. This is of special interest because the exact
mechanism underlying a shunt from the COX to the 5-LO
pathway in osteoblasts remains unknown. However, this
knowledge could be crucial for therapeutic intervention in OA.
The actual therapies for OA are somewhat limited to a
decrease in pain in affected joints with the use of either non-
Figure 5
Regulation of FLAP mRNA expression by 1,25(OH)2D3 and TGF-β in  normal and osteoarthritis osteoblasts Regulation of FLAP mRNA expression by 1,25(OH)2D3 and TGF-β in 
normal and osteoarthritis osteoblasts. Confluent cells were incubated 
for their last 48 hours in Ham's F12/DMEM medium containing 0.5% 
BSA in the presence or absence of 50 nM 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3; D3), 10 ng/ml transforming growth factor-β (TGF-β), or 
both. Osteoarthritis (OA) osteoblasts were separated into low and high 
OA as described in the legend to Figure 1. 5-Lipoxygenase-activating 
protein (FLAP) expression was measured as described in the legend to 
Figure 2. Values are means ± SEM. Normal samples, n = 3; low and 
high OA, n = 4 for each group.
Figure 6
Modulation of PGE2 production by 1,25(OH)2D3 and TGF-β in osteoar- thritis osteoblasts Modulation of PGE2 production by 1,25(OH)2D3 and TGF-β in osteoar-
thritis osteoblasts. Confluent cells were incubated for their last 48 
hours in Ham's F12/DMEM medium containing 0.5% BSA in the pres-
ence or absence of 50 nM 1,25-dihydroxyvitamin D3 1,25(OH)2D3; D3), 
10 ng/ml transforming growth factor-β (TGF-β), or both. Top: prostag-
landin E2 (PGE2) was measured in conditioned medium with the use of 
a very selective ELISA. Values are means ± SEM for n = 7 preparations 
for both low and high osteoarthritis (OA) osteoblast groups. *p < 0.01; 
**p < 0.05 compared with the respective basal value for the low or high 
OA group. Bottom: representative Western blot analysis of cyclooxyge-
nase-2 (COX-2) production in five OA osteoblast preparations in 
response to 1,25(OH)2D3, TGF-β, or both. Loading between samples 
was measured by western blot analysis of actin. Low OA and high OA, 
n = 7 for each group for PGE2 determinations.Available online http://arthritis-research.com/content/8/6/R181
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selective NSAIDs [48-50] or the selective coxibs [48,51-53].
These later compounds are aimed at decreasing the inducible
COX-2 activity responsible for prostaglandin synthesis. The
long-term treatment of OA patients with selective inhibitors of
COX-2 could promote the production of LTs. In an animal
model of arachidonic acid-induced inflammation, Goulet and
colleagues [54] showed that an NSAID can suppress almost
completely the inflammatory response in 5-LO-deficient mice,
in contrast with wild-type animals. Hence, PGE2 produced via
both COX-1 and COX-2 could modulate the activity of 5-LO
in these animals, which is reminiscent of the fact that PGE2
inhibits 5-LO activity [55].
We showed previously that in OA subchondral osteoblasts
long-term treatment with NS-398, a selective COX-2 inhibitor,
leads to an increase in LTB4 production [12]. The present
study demonstrated that the induction of LTB4 production in
response to NSAIDs or NS-398 in OA osteoblasts involved no
major modification of 5-LO expression, in contrast to the situ-
ation observed in OA chondrocytes [56]. In fact, the increase
in LTB4 was either due to an upregulation of FLAP expression
in high OA osteoblasts in response to inhibitors of PGE2 pro-
duction or it was already high in the low OA subgroup. FLAP
is known to present arachidonic acid to 5-LO for its synthesis
into LTs [25,27]. Furthermore, this elevated FLAP expression
could be curbed by exogenous PGE2. This was especially true
in the low OA subgroup presenting low PGE2 levels, whereas
in the high OA subgroup with already high PGE2 levels the
addition of exogenous PGE2 failed to modify FLAP expression.
These results indicate that the balance of PGE2 levels in OA
osteoblasts is actually driving the expression of LTs, and con-
versely that chronic inhibition of COX may be leading to the
synthesis of LTs. Given that LTs are more pro-inflammatory
than prostaglandins, this would suggest that chronic inhibition
of COX could lead to potential harmful effects. Such a shunt
from the COX to the 5-LO pathway has previously been
observed in other cell systems, in particular in macrophages
[13,14,57].
This shunt was either related to an increase in 5-LO expres-
sion or that of FLAP through an IL-10-dependent or IL-18-
dependent pathway in other cell systems. Indeed, PGE2-
driven IL-10 synthesis in monocytes/macrophages in vitro has
been shown to inhibit LTB4 production by these cells [24],
whereas in neutrophils IL-18 stimulates the synthesis of LTs
[32]. In subchondral osteoblasts, a link between IL-10 and
PGE2 could not be established because IL-10 synthesis by
either normal or OA osteoblasts was very low, close to the limit
of detection. This possibility therefore seems very weak. In
addition, endogenous IL-18 levels in subchondral osteoblasts
were also weakly linked with endogenous PGE2 levels. In the
synovial fluid of patients with OA of the knee, a linear relation-
ship has been established between IL-18 and PGE2 or IL-6
[47]. Indeed, in OA osteoblasts treated with either an inhibitor
of PGE2 synthesis or exogenous PGE2 we observed a slight
decrease in IL-18 or a slight increase, respectively (not
shown). However, considering the relationship established
between PGE2 and IL-18 in this study it would be surprising if
IL-18 were to have a significant role.
The modulation of LTB4 production in OA osteoblasts was
also linked to alterations of FLAP expression in these cells in
response to 1,25(OH)2D3 and TGF-β as observed in other cell
systems [30,31,44,58]. However, this regulation by
1,25(OH)2D3 and TGF-β seemed to be linked with the actual
physiological state of the cells. Indeed, low PGE2 OA osteob-
last producers responded more readily than normal osteob-
lasts to stimulation with 1,25(OH)2D3. In contrast, the
response to TGF-β challenge was somewhat offset in both low
and high PGE2 producers. This might have been due to the
endogenous high TGF-β levels produced by all OA osteob-
lasts [23] and hence to a possible chronic desensitization to
further TGF-β challenge in vitro. However, concomitant incu-
bation with 1,25(OH)2D3 and TGF-β was able to stimulate
FLAP expression to the levels observed in normal cells under
similar conditions. Again, this would suggest that FLAP is the
key enzyme that controls the production of LTs in OA
osteoblasts, rather than 5-LO, which showed little variation of
expression regardless of treatment. This is in contrast to the
situation observed with several cell systems in which
1,25(OH)2D3 and TGF-β enhanced the expression of 5-LO
[28,29,45,46] or both 5-LO and FLAP [44]. Because the
activity of 5-LO can also be modulated by its phosphorylation
state [59], this could also be a possible mechanism of control
in OA osteoblasts; this was not investigated in this study.
Figure 7
Relationship between PGE2 and IL-18 levels in normal and osteoarthri- tis osteoblasts Relationship between PGE2 and IL-18 levels in normal and osteoarthri-
tis osteoblasts. Confluent cells were incubated for their last 48 hours in 
serum-free medium containing 1% insulin-transferrin-selenium mix 
(ITS). Prostaglandin E2 (PGE2) and IL-18 levels were measured in 
supernatants with the use of selective ELISA. Data are values for indi-
vidual cell cultures. Osteoarthritis (OA) osteoblasts were separated 
into low and high OA as described in the legend to Figure 1. Normal 
samples, n = 10; low OA, n = 12; high OA, n = 14 samples.Arthritis Research & Therapy    Vol 8 No 6    Maxis et al.
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However, the effect of 1,25(OH)2D3 and TGF-β on PGE2 pro-
duction is different from that on LTB4 production in OA oste-
oblasts. Indeed, TGF-β stimulated PGE2 production to similar
levels in both the low and high OA subgroups, a situation
linked with its modulation of COX-2 synthesis. In contrast, the
effect of 1,25(OH)2D3 on PGE2 production was weaker than
that on LTB4 production, also reflected by its effect on COX-2
synthesis. On its own 1,25(OH)2D3 had no effect, whereas it
inhibited the effect of TGF-β in the low OA osteoblasts sub-
group only. In normal human osteoblasts, 1,25(OH)2D3 was
previously shown to inhibit PGE2 production both alone and in
response to TGF-β [60], a situation similar to our low OA oste-
oblasts subgroup. In contrast, in the mouse osteoblast-like
MC3T3-E1 cells, 1,25(OH)2D3 is without effect, whereas it
inhibits PGF-2α-induced PGE2 production [61]. TGF-β alone
can stimulate PGE2 production in serum-free conditions in
MC-3T3-E1 cells and can potentiate the effect of IL-1, a situ-
ation not observed in the presence of 10% serum [62]. As our
assays were performed in serum-free conditions for PGE2 pro-
duction, our data are similar to those in this situation. Taken
together, the results for LTB4  and PGE2  production in
response to 1,25(OH)2D3 and TGF-β indicate that the produc-
tion of LTB4  is more sensitive to 1,25(OH)2D3  treatment
through its effect on FLAP expression, especially in the high
OA osteoblasts group, whereas the production of PGE2 is
sensitive to TGF-β in both groups. Moreover, the overall effect
of 1,25(OH)2D3 and TGF-β would promote both PGE2 and
LTB4 production in all OA osteoblasts, whereas their effect is
more evident on the production of PGE2.
Although OA osteoblasts could separate OA patients into two
groups producing either low or high levels of PGE2, these cells
showed similar phenotypic characteristics and produced sim-
ilar levels of collagen type 1, although at higher levels than in
normal osteoblasts. This suggests that neither PGE2 nor LTB4
has a direct role on bone tissue sclerosis in OA. However, ele-
vated LTB4 levels could locally influence bone resorption, lead-
ing to an increase in bone resorption indices. Clinical studies
have reported both increases and an absence of change in
bone resorption parameters in OA patients [63-70], a situation
that could be linked with the endogenous PGE2 production by
OA bone tissue and thereby that of LTB4. Indeed, some
authors have suggested that patients with progressive knee
OA had increased bone resorption parameters. Last, osteob-
lasts were prepared from the overall subchondral bone plate
of the tibial plateaus of OA patients, thus not isolating
subchondral bone from lesional and non-lesional areas of
articular cartilage. Although this may be considered a limitation
of the present study, our own previous results by using oste-
oblasts isolated from bone tissue underlying lesional and non-
lesional areas of cartilage did not show any overt differences
in terms of phenotype or behavior [71]. Moreover, OA osteob-
lasts isolated from the trabecular bone region below the
subchondral bone plate show similar results to those of OA
osteoblasts from the subchondral bone plate [72,73], and OA
bone tissue from non-weight-bearing areas also show similar
alterations to those in joints [74,75], thus indicating that the
bone tissue alterations in OA patients are generalized rather
than localized events.
Conclusion
We have shown that in OA osteoblasts the synthesis of LTs is
linked to the tight regulation of FLAP expression, not that of 5-
LO. Moreover, the basal synthesis of LTs is linked to a variable
expression of FLAP in OA osteoblasts as a result of their
endogenous production of PGE2. Both 1,25(OH)2D3  and
TGF-β modulated the expression of FLAP and thereby that of
LTB4. IL-10 is not involved in the regulation of the synthesis of
LTs in OA osteoblasts, whereas IL-18 levels are linked with
PGE2 levels.
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